Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGFβ
High potency anti- α vβ8 mAb licensed from University of California San Francisco and
anti-αvβ6/αvβ8 mAb licensed from Panorama Research Inc.
Both mAbs expected to start Phase 1 testing in 2022
Capital and resources in place to advance multiple programs into clinical development
Company to host conference call and webcast today, Tuesday, June 1, 2021 at 8:30 a.m. ET
Conference Call and Webcast Information:
Corbus management will host a conference call and webcast presentation for investors, analysts, and other interested parties today, Tuesday, June 1, 2021, at 8:30 a.m. ET.
To participate on the call, please dial (877) 407-3978 (domestic) or (412) 902-0039 (international). The live webcast will be accessible on the Events page of the Investors section of the Corbus website, www.corbuspharma.com, and will be archived for 90 days.
https://finance.yahoo.com/news/corbus-pharmaceuticals-licenses-two-integrin-110500226.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.